Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

Phase 3 trial results show levacetylleucine improves SARA scores in patients with the rare disorder ataxia-telangiectasia.

Phase III trial successfully achieved its primary endpoint and key secondary endpoints with high statistical significance Levacetylleucine demonstrated clinically meaningful improvements in ...

IntraBio Inc. today announced positive topline results from its pivotal Phase III IB1001-303 clinical trial, "Effects of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T): A Randomized, ...

If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

As IntraBio works to grow the global treatment market for Aqneursa in Niemann-Pick disease type C, the company is already ...

IntraBio’s Aqneursa receives European Commission’s marketing approval for treatment of Niemann-Pick Type C disease: Austin, Texas Saturday, January 24, 2026, 14:00 Hrs [IST] I ...

For Fore people, endocannibalism was a mortuary rite intended to honour the dead and keep their essence alive within the ...

IntraBio Inc. today announced that the European Commission granted marketing authorization to AQNEURSA® (levacetylleucine) for the treatment of neurological manifestations of Niemann-Pick Type C (NPC) ...

Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for ...

Brits plagued by forgetfulness are being told to get their vitamin levels checked, as running low on a crucial nutrient can trigger symptoms similar to dementia. The NHS states that a lack of a ...

ProVerum Limited, a medical device company focused on innovative, safe and effective solutions for treating benign prostatic ...